The Buzz Surrounding Chemesis International Inc. (CSE: CSI) (OTC: CADMF)



Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, with operations in California and exploring expansion through Latin America.

Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution and retail. Chemesis has seed to sale operations, allowing for cost-effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods to provide consumers with quality cannabis products.

Investor Recap



The Process


Starting with our state of the art grow facility in Puerto Rico, which showcases a 2000+ grow light capacity and a 30,000+ lb overall grow capacity, Chemesis has multiple expansion opportunities currently under review in both Puerto Rico and California.


Chemesis is able to offer it’s clients all types of extractions, formulations & products, specializing in BHO Extraction, Alchohol Extraction, and CO2 Extraction and currently has the capacity to process over 2000lbs of raw material per day.


Chemesis is in sync with distributors around the world. With new regulations impacting the California market, we will emerge as a fully compliant first mover. In the Puerto Rico market, Chemesis has an established presence serving the entire island from seed to sale.


Chemesis is currently retailing exclusive products in Puerto Rico and actively engaging retail storefronts in the California market. In addition, Chemesis is working to open exclusively branded shops in multiple marketplaces.

Current Operations


Puerto Rico




Chemesis specializes in, and has invested in the equipment for, multiple extraction processes – BHO Extraction, Alcohol Extraction, CO2 Extraction, and others – and currently has the capacity to process over 2000lbs of raw material per day.   

Exclusive Brands


California Sap is one of the most rewarded companies in the cannabis industry today. Known for their experience, their purity, and their incredible products, Chemesis is excited to offer this exclusive brand.


Natural Ventures, our operations headquartered in Puerto Rico, holds strategic partnerships with an expanding number of leading brands in the cannabis industry spanning across multiple countries.


SAP Global is a state-of-the-art production facility located strategically in Cathedral City, California. The facility is able produce high quality legally compliant cannabis products for distribution in California.


Desert Zen Distribution & Transport, headquartered in the Coachella Valley, is all your California cannabis distribution needs under one roof.



Net Income Projections

[wpdatachart id=2]

Data provided by Chemesis International Inc.



Recent Developments

Chemesis International Inc. Signs Binding Agreement To Acquire 100% Of Colombia Based Cannabis Company – La Finca Interacviva-arachna Med

Chemesis International Inc. has entered into a binding letter of intent (LOI) to acquire 100 per cent of Colombia-based La Finca Interacviva-Arachna Med SAS, an integrated cannabis company that has been licensed and operational in Colombia since October, 2017.

La Finca has access to over 1,000 acres of outdoor cultivation land and is aggressively exploring opportunities to expand. It is a founding member for the “Association for the Promotion of Hemp Growing,” a non-profit entity that is concentrated on providing education and promoting the expansion of cannabis plantations, while ensuring the growth of high-quality crops through technical advice. The company’s cultivation program is based on a decentralized model with partner farmers throughout the country, allowing small farmers to quickly generate high-quality crops. Currently, La Finca has relationships with over 2,000 farming families across Colombia through various co-ops that comprise its land package.

La Finca also has a partnership with the largest university in Colombia, Universidad Nacional de Colombia, to develop seed strains that improve the yield of biomass and flower while shortening crop cycles. It has also partnered with Universidad Distrital Francisco Jose de Caldas, which focuses on the educational aspects of cannabis cultivation. The university provides distance education as well as in-class instruction to educate farmers on cannabis crops, ensuring they are able to produce high-quality crops.

La Finca currently has several manufacturing relationships and $2.5-million working capital available to expand its operations. The company has a manufacturing agreement for licensed cosmetic products under the La Finca brand. These products are licensed through the Instituto Nacional de Vigilancia de Medicamento (INVIMA) which is Colombia’s equivalent to the U.S. Food and Drug Administration. The company is heavily involved with INVIMA ensuring compliance with all regulations and health requirements.

Colombia is located close to the equator and boasts a 12-hour sun cycle that occurs year round, allowing for harvesting to occur 365 days a year (1). The mountainous geography of Colombia provides different thermal floors which allow for cultivation to occur in multiple climates, simultaneously. Colombia also has many free-trade agreements that will allow for cost-effective export of cannabis products around the world. The company believes La Finca is particularly well positioned in a country that is quickly adapting cannabis regulations, thus providing an extremely lucrative investment opportunity for both short- and long-term growth.

“Chemesis is continuing its expansion into the Latin American market, a region the company believes is poised for international growth and expansion,” said Chemesis chief executive officer Edgar Montero. “With the acquisition of La Finca, the company will acquire an asset in a country that is developing its cannabis industry for distribution around the world. We continue to execute our business plan that is focused on building long-term growth in key markets around the world.”

The company will acquire La Finca for $13.5-million in a combination of cash and common shares of the company to be determined upon execution of the definitive agreement. All stock issued will be subject to a 36-month phased lock-up period. Closing of the transactions contemplated by the LOI are subject to regulatory approval.


Chemesis International Inc. intends to enter the recreational and medical cannabis market in Canada. The Company is reviewing possible joint ventures, agreements or acquisitions in distribution, manufacturing, and product development spaces. Chemesis intends on leveraging its assets, brands and management expertise to gain market share in Canada. Chemesis is presently performing due diligence on fully licensed and operational cannabis companies in Canada.

Canada has significant opportunity in both recreational and medical markets, with the Canadian cannabis market expected to generate up to $7.17-billion in 2019. The company sees major opportunities in Canada from high-quality manufacturing to brands that have developed a strong presence in the market. Chemesis aims to introduce Canadian consumers to its portfolio of brands which includes California Sap, the company’s flagship brand. California Sap has been recognized in California since 2012, with 25 gold rankings for best CO2, best topical, best product, best concentrate, best cartridge, highest terpene and more.

“The company is looking at multiple opportunities in Canada that will allow us to enter the market and gain a strong presence with minimal regulatory hurdles,” said chief executive officer Edgar Montero. “Chemesis is only evaluating businesses that have met regulatory and compliance standards. This allows the company to enter into the market with our assets, and expertise without unnecessary delay. The introduction of California Sap and our other brands will allow Canadians the ability to purchase premium brands, that are extremely accomplished in California. As we continue to execute our business plan, Chemesis will look for acquisitions and partnerships that bring growth and shareholder value.

Chemesis International Inc. & Rapid Dose Therapeutics Sign A Definitive Agreement For Quickstrip Oral Thin Strips

Chemesis International Inc. has signed a definitive agreement, providing a managed strip service agreement enabling Chemesis to produce QuickStrips infused with cannabis oils.

RDT’s innovative QuickStrip is an easy-to-use, safe and effective oral fast-dissolving drug delivery system, developed in conjunction with McMaster University through the renowned Adronov Research Group, which provides accurate dosing and potency.

Under the terms of the agreement, Chemesis will receive rights to produce, distribute and sell QuickStrip products, with rights for cannabis markets in California. With Chemesis’s state-of-the-art facility, the company believes this partnership with RDT will further strengthen its position in the California cannabis market, by allowing the company to use a convenient drug delivery system that can target a variety of consumers and also allow them to use cannabis products in a new way. The company will continue to position itself to capitalize in this growing market with innovative and effective products.

“RDT is an innovator in the drug delivery world, making this an excellent opportunity for Chemesis,” said chief executive officer of Chemesis, Edgar Montero. “QuickStrip is composed of therapeutic products and they also provide a drug delivery system that is quick, convenient, precise, discrete, convenient for travel and an alternative for those who have problems swallowing pills. The company believes it can use this drug delivery system to target a wide range of consumers and we look forward to distributing products in the near future.”

“RDT is pleased to be partnering with Chemesis to provide California’s consumers with a delivery method they can count on that begins the move away from inhalation for dosing therapeutic products,” explained Mark Upsdell, chief executive officer of RDT. “Chemesis has developed strategies, partnerships, quality oil production and distribution channels that will allow QuickStrip to expand rapidly into the California market. We will work directly with Chemesis in developing additional white label partnerships with manufacturers and distributors in California.”

Chemesis International Inc. Signs Agreement For Packaging, Fulfillment & Distribution For Julian Marley Juju Royal Brand

Chemesis International Inc. has reached a fulfilment and distribution agreement for the ultrapremium Julian Marley JuJu Royal brand. The packaging, fulfilment and distribution will be for all of JuJu Royal’s Southern California operations.

This highly sought-after brand consists of carefully crafted, quality cannabis products that will be handled in the company’s Desert Zen facility, based in Cathedral City, Calif. These products meet Julian Marley’s demanding standards and are currently being sold in multiple states. The catalogue of products includes a variety of cannabis products and signature strains exclusive to JuJu Royal.

“The agreement for JuJu Royal is another example of Chemesis’s ability to delivery consistent quality products, validating management’s business plan and growth strategy,” said chief executive officer Edgar Montero. “Brands that require high-quality services are recognizing our ability to consistently handle full compliance capacity for all of their high-quality products. As Chemesis gains more exposure in the market place, we anticipate the need for quality reliable services to continue to rise. Agreements such as this will ensure we are able to build stable, long-term value for the company.”

Chemesis International Inc. Enters Into the Cannabis Edibles Market

Chemesis International Inc. announced that it will be entering into the cannabis edibles category. Chemesis intends to use its existing facilities and licenses to streamline its entry into the expanding edibles market, providing services for businesses that need manufacturing, packaging, and distribution while maintaining compliance.

Recent changes in California regulations require companies to ensure they are selling products with clean tested cannabis while ensuring all processes are fully compliant to state and municipal laws. Businesses are eager to find companies that are able to operate in California’s legal framework. The market for cannabis in California is estimated to hit $7.7 billion by 20211. Chemesis believes it has assets and services that are key for businesses to thrive in a compliant marketplace.

Chemesis will be using the recently acquired Desert Zen Fulfillment facility for this edibles expansion and anticipates products to be launched in Q1 2019. Chemesis intends to enter the edible market with gummies, chews, chocolates, brownies, cookies, and other edibles. These products will be manufactured for Chemesis’ own brands as well as white labelling for other businesses.

“Chemesis continues to enter into the most lucrative and important product categories,” said Edgar Montero, CEO of Chemesis. “Management is executing a strategic business plan that allows businesses to use Chemesis for all of their products and needs, making us a one stop shop. The recent regulation changes have put pressure on businesses to find compliant manufacturing and distribution; Chemesis continues to ensure it is a top choice for companies. Entering into the edibles category is another strategic move in our long-term business plan to ensure we build long term relationships that deliver a steady revenue stream.”

Chemesis International Inc. Announces Appointment Of New Chief Financial Officer & Option Grant

Chemesis International Inc. has appointed Eli Dusenbury as the company’s new chief financial officer and has granted options.

Mr. Dusenbury has extensive experience in public accounting providing services to both public and private sector clients reporting in Canada and in the U.S., over a broad range of industries, including but not limited to technology, agriculture, engineering, mining & exploration, manufacturing and financing. Mr. Dusenbury obtained his Chartered Professional Accountant designation in 2011, and holds a BBA in business and accounting from Capilano University.

The Company wishes to thank Mr. Lee for his service as CFO during the Company’s growth and wishes him the best in his future endeavours.

The Company announces that on September 14, 2018 it has granted an aggregate of 150,000 incentive stock options to a consultant of the Company. The options are exercisable at $1.00 per share for a one-year term. The Company announces an additional stock option grant of 200,000 incentive stock options to an Officer of the Company. The options are exercisable at $1.74 CAD for a five-year term. There are also no vesting provisions for either option grant other than a four-month hold period from the date of the grant in accordance with the Company’s Stock Option Plan.

Chemesis International Inc. Enters into the Cannabis Infused Beverage sector

Chemesis International Inc. announce it will be entering into the cannabis infused beverages market. Chemesis will leverage licences and assets it has recently acquired to build out production, storage, and a transportation network for its cannabis infused beverages. The cannabis beverages category includes sports drinks, teas, sodas, coffees, shots, water, and other health and wellness beverages.

With cannabis sales projected to triple from approximately $5.4 billion USD in 2015, to $16 billion USD in 2020, according to a market research, Chemesis sees a significant growing opportunity in the beverages market1. Entering into the cannabis beverages market is the next logical step for the Company, as its current facilities and licenses allow this to be accomplished in a relatively short period of time. The Company can accomplish this by leveraging its state licenses for production, distribution, and transportation. Chemesis intends to provide white labelling services for companies, as well as introducing beverages for its own brands. Chemesis will be using the recently acquired Desert Zen Fulfillment facility for this expansion and anticipates products to be launched in Q1 2019.

“Entering into the cannabis infused beverage market is an extremely important step for Chemesis,” said CEO Edgar Montero. “The cannabis market is expanding into more product categories, and Chemesis is identifying opportunities that will build long term value and consistent revenues. Our existing licenses and facilities will allow us to expand our portfolio of products without the added regulatory delays. The company will continue to ensure it expands and creates a footprint in markets and product spaces that align with our ambitious business plan.”

Chemesis International Inc. Announces Global Expansion Through Wholly Owned Subsidiary Chemesis Latin America

Chemesis International Inc. has opened its wholly owned subsidiary, Chemesis Latin America. Through this subsidiary, the company is exploring and completing advanced due diligence on opportunities for cultivation, production and export from the Latin American market. The company believes it will be able to quickly gain market share in Latin America through the use of its networks and existing expertise.

Chemesis’s long-term growth strategy is focused on international expansion. Globally, regulation changes are occurring for both medical and recreational cannabis, and as these changes occur, Chemesis intends to be a first mover by leveraging its existing networks and developing brands suited for the Latin American. Mexico is a great example of these changes, as president-elect Andres Manuel Lopez Obrador, who has the job of overseeing rule making and regulations around Mexico’s new marijuana law, unveiled a plan to change the country’s drug strategy in several big ways.

Colombia, another frontrunner in the Latin American cannabis market, is rapidly growing its capabilities. The government is hoping to grow up to 40.5 tons of cannabis per year, which would account for approximately 44 per cent of the licences issued globally. Colombia is estimated to capture as much as one-fifth of the global market, a value of $40-billion a year.

“Chemesis Latin America is a big step forward in our global growth strategy,” said chief executive officer, Edgar Montero. “We believe Chemesis has a major advantage in this region, as the recent acquisition of Natural Ventures can be leveraged to quickly capitalize on upcoming opportunities. With progressive regulations, Latin America becomes a key market that will be a major part of our portfolio. The company has positioned itself to take advantage of significant opportunities in both Mexico and Colombia. This allows Chemesis to execute on its ambitious growth strategy to identify opportunities that will build long-term shareholder value.”

The company plans to announce the specific countries and jurisdictions where it will be operating in the near future.

Chemesis International Inc. Signs Definitive Agreement To Acquire 80% Of Puerto Rico Based Natural Ventures Pr Llc

Chemesis International Inc. has entered into a definitive agreement to acquire 80 per cent of Natural Ventures PR LLC via its subsidiary Chemesis PR, a 100-per-cent-Puerto Rican company. The agreement amongst the parties has been submitted to the Puerto Rico Medical Cannabis Board for approval as per required by its regulatory framework. Natural Ventures is a seed to sale, medical cannabis company based in Caguas, Puerto Rico, a United States territory. Natural Ventures represents a significant opportunity that will catapult Chemesis into position as a leader in both medical and recreational cannabis cultivation and manufacturing.

Natural Ventures has been operational since early 2017 and currently is expanding to meet its growing patient demand. Natural Ventures is licensed to cultivate 100,000 square feet of cannabis and has 35,000 square ft of manufacturing floor space for high-quality cannabis products. It is currently producing solvent and carbon-dioxide-based extraction for its oil-based products, and it also is producing edibles and other cannabis products.

Puerto Rico legalized medical cannabis for qualifying health conditions in 2015 and permits the use of medical cannabis derivatives only (capsules, extractions, lotions, patches, edibles, flower and oils). Currently, there are 18 preapproved health conditions including HIV, cancer, multiple sclerosis, migraines, anxiety and epilepsy that are eligible to be treated with medical cannabis. Chemesis is poised to meet demand as the island continues to expand the number of qualifying conditions, and more patients receive permits.

“The acquisition of Natural Ventures is a very significant landmark for Chemesis,” said chief executive officer of Chemesis, Edgar Montero. “This acquisition gives the company access to a new consumer base as well as additional revenue opportunities. The operations in Puerto Rico unlock the ability to serve a large population for a variety of medical conditions, while being able to control costs and quality. The addition of Natural Ventures into the Chemesis family fits into our business model and growth strategy, as it will not only provide a strong benefit to our revenue stream but will unlock other opportunities in the global marketplace that are extremely important,” said Mr. Montero.

In exchange for an 80-per-cent interest in the capital stock of Natural Ventures PR LLC, the company will pay $2.25-million (U.S.) cash and $1,682,085 (U.S.) of stock valued at $1 (Canadian) per common share, subject to a 36-month phased lockup. Closing is subject to Puerto Rico Medical Cannabis Board approval which is anticipated within 30 days. The company has also agreed to make a convertible loan or capital contribution to Natural Ventures in the aggregate amount of $750,000 (U.S.) on an as-needed basis for expansion purposes.

Chemesis International Inc. Acquires 100% Of Desert Zen

Chemesis International Inc. has entered into and closed a definitive agreement to acquire 100 per cent of Desert Zen, a state-compliant, recreational and medicinal cannabis manufacturing, distribution and transportation company based in Cathedral City, Calif. This acquisition will allow Chemesis to increase its resources and significantly expand its foothold in the rapidly growing California market.

Desert Zen’s current facility is licensed under state and local laws to manufacture, package, distribute and transport quality cannabis products for recreational and medicinal uses. Desert Zen has a large existing network throughout the state of California that currently serves farmers and dispensaries, as well as other manufacturers, distributors and transporters. As a fully compliant cannabis manufacturer, distributor and transporter working with other fully compliant vendors, Desert Zen is able to track all products, monitor safety and ensure that all seed-to-sale laws are followed throughout the entire supply chain. Desert Zen’s catalogue of products includes a variety of cannabis products and will also include Chemesis’s flagship brand of California sap premium cannabis oils.

“State-wide compliance at each regulatory level in California requires substantial effort, and Chemesis is pleased to continue its growth as one of the few fully compliant first movers in the California market,” said Chemesis chief executive officer Edgar Montero. “Chemesis now has greater flexibility in its operations and can serve its customers more fully and efficiently. In addition, the acquisition of Desert Zen brings new product manufacturing, distribution and transportation opportunities to Chemesis’s considerable oil extraction capabilities.

“Desert Zen is an established cannabis manufacturer, distributor and transporter that continually is expanding its operations and will allow the company to further execute its growth strategy in the state of California,” said Mr. Montero. “The Desert Zen management team has a wealth of experience and an established network of growers, manufacturers and dispensaries. As Chemesis continues to grow, acquisitions such as this will ensure Chemesis is able to build consistent, long-term value for the company.”

Chemesis International is acquiring a 100-per-cent interest in Desert Zen in exchange for $500,000 (U.S.) of the company’s common stock at a deemed value of $1 (Canadian) per share, subject to a 36-month phased leakout restriction.

  1. Dan 1 year ago

    The U.S will legalize cannabis eventually.

  2. Ming 1 year ago

    That’s a nice landing page

  3. Devin 1 year ago

    The cannabis market is growing really fast. Some of the cannabis stocks hit all-time high.

    • Jeff Macke 1 year ago

      market not showing any weakness, the idea of mainstream retailers showing interest in the cannabis market will continue to drive the market higher

  4. Gregory Jenkins 1 year ago

    Is the hype real around this mj space? I keep hearing from friends about all these big moves. But I am still not sold but this company chemsis looks great. I will do some more research – thanks GJ

    • Vanessa Louie 1 year ago

      #cannabis companies have a unique opportunity to gain a head start on foreign competition. What will international expansion mean for these businesses and how can they ensure long-term success?

    • James Schwarz 1 year ago

      Cannabis has many uses and can be applied in multiple ways, it is truly gods natural remedy. The cannabis market will grow rapidly in the U.S. once it is legal on a nation-wide scale

      • Warren Mo 1 year ago

        Canada has finally admitted that it is gods natural remedy, legalization has proven that and now $CSI has strategically begun positioning in Canada which will contribute to their revenue and future growth

        • Steve Shanahan 1 year ago

          I stand resolutely against the legalization of cannabis for recreational use in Canada. Users of our roads will be less safe, work site accidents will grow and low income families will be forced to raise their families in the stench of marijuana smoke from neighbours. A new low.

          • Wayne Turner 12 months ago

            Canadians know that driving while high on marijuana causes a risk to road safety, but they don’t seem to understand cannabis impairment fully,

        • Todd Sonoga 12 months ago

          Canadian legal cannabis literally sold out across the country, yet a lot of profit taking leading to a blood bath in the market. #market #asymmetry #CannabisCanada

    • Zia Marcus 1 year ago

      The cannabis market is prime to continue to grow so taking some strategic longs is important. California’s cannabis market is huge, I do own a position in $CSI @1.74. I want to add but looking for a pullback first

      • Edward Gerety 1 year ago

        Chemesis should invest in a cannabis wellness resort that would cater to patients needing medical cannabis treatment

    • Eugene Honders 12 months ago

      Canadian pot shops are seeing inventory being bought up faster than estimated, Colorado annual pot $ passed $1 billion last week, UK and Germany becoming more open to cannabis. The cannabis market is not even fully realized anywhere IMO

  5. Warren 1 year ago

    A lot of cannabis stocks are trading at a very high valuation. People has high expectation about it.

    • Miguel 1 year ago

      TLRY is a 10 billion market cap company and is making no profit.

    • Aaron Thommpson 1 year ago

      there are many untapped methods of taking cannabis, $CSI just introduced oral strips to the table. They will provide instant relief. This is a win for medical and recreational users

    • Peter Alexander 1 year ago

      they will continue to get higher valuations as more states are legalizing. Canada is fully legalizing on Wednesday…

      • Jonathan Bin 1 year ago

        The day is finally here! 95 years after it was criminalized in Canada, the recreational use of #cannabis is now legal. Thank you to the activists, educators & community leaders who paved the way for this momentous occasion #legalization #BillC45 #C45 #marijuana #cannabiscommunity

        • Bill Peters 1 year ago

          wise words from Trudeau “The old approach to #cannabis didn’t work. It was too easy for our kids to get it and gangs & drug dealers were reaping the profits. That changes from now on”

        • Sarah Tremblay 12 months ago

          Cannabis stores across Canada face shortages. Canadians the age of majority in their province can grow up to four plants a household, yet there is no legal means to obtain seeds.

  6. Richard 1 year ago

    Consumers claim to prefer legal to illegal cannabis – and lower legal prices hit illegal sales more than lower illegal prices hit legal sales.

    • Tim Collins 1 year ago

      of course as cannabis is more regulated, we can track where it is cultivated including the potency, etc. There is too much unknown buying from an illegal dealer

    • Phil Wahba 12 months ago

      a well regulated product is much safer. It will definitely get some new customers as illegal cannabis may have contaminants where legal products are guaranteed to be safe

  7. Ryker 1 year ago

    There is news saying that Coca-Cola want to produce cannabis drinks. If it is true, it will be a big news.

  8. Dalton 1 year ago

    Everyone is chasing cannabis stock these days, leading by TLRY

    • Calvin 1 year ago

      It go back down again. That was crazy move.

    • Ruben 1 year ago

      I don’t like the sudden move like these. I hope it will grow slowly and healthy.

Leave a Comment

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For chemesis international inc. financial news dissemination and PR services, has been compensated fifteen thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: